Adoption of all the proposed resolutions, except for the 34th and 36th resolutions, as recommended by the Management Board
Announcement of the departure of Jaime Arango, Chief Financial Officer, replaced by Stéphane Postic
MedinCell’s Ordinary Annual and Extraordinary General Meeting was held on September 12, 2023, at the company’s headquarters (3 rue des Frères Lumière, 34830 Jacou). It was chaired by Mr. Anh Nguyen, Chairman of MedinCell’s Supervisory Board.
With a quorum of 62.70% the shareholders have adopted the resolutions proposed by the Management Board, including the approval of the annual consolidated accounts for exercise ended March 31, 2023, the remuneration policy applicable to the Chairman and members of the management board, to the Chairman and the members of the Supervisory Board as well as financial delegations granted to the management Board.
The General Meeting also renewed the mandates of four members of the Supervisory Board: Mr. Philippe Guy, Ms. Tone Kvåle, Ms. Virginie Lleu and Mr. Anh Nguyen.
As recommended by the Management Board, resolutions 34 and 36 were rejected.
The replay of the general meeting and the detailed voting results will soon be available on the MedinCell website.
MedinCell has also announced that its Chief Financial Officer and member of the Management Board, Jaime Arango, will leave the Company on September 27 to pursue other professional opportunities. He will be replaced by Stéphane Postic during a transition period. The company will take advantage of this period to adapt the financial and capital markets functions to its new challenges.
Graduated from EM Lyon, Stéphane Postic has more than 25 years of experience in finance, including 20 years in supporting biotechnology companies, including Genfit (Euronext: GNFT), Da Volterra, and Egle Therapeutics. He managed corporate finance, participated in financing and IPO operations and notably interacted with the European Investment Bank.
“I would like to thank Jaime for his commitment and contribution to MedinCell’s success. He supported the Company through its IPO and the commercialization of our first product UZEDY,” said Christophe Douat, Chairman of MedinCell’s Management Board. “MedinCell has entered a new era that will require strengthening our financial and capital markets functions to adapt them to the next stage of our growth. Welcome to Stéphane, who will give MedinCell the full benefit of his experience.”